Optieum is driving the evolution of next-generation CAR-T cell therapy with precision-engineered CAR constructs. The company's CAR discovery engine focuses on optimizing the binding domain of CAR to enhance immune cell function, delivering robust therapeutic efficacy.
Through its core platform technology, the Eumbody System, Optieum utilizes empirical methodologies to identify optimized CARs, accelerating the development of advanced CAR-T cell therapies. This approach dynamically harmonizes scFv sequences via empirical evaluation, significantly enhancing the functional capabilities of T cells.
The company is focused on pushing the boundaries of solid tumor treatment using next-generation CAR constructs engineered to achieve the optimal activation threshold for T-cells. These constructs demonstrate superior proliferative capacity, prevent antigen escape, and exhibit exceptional reactivity against advanced tumor profiles.
Optieum’s pipeline includes programs targeting FAPa for solid tumors, CD19 for hematological malignancies and autoimmune disorders, and an undisclosed discovery program.
